UNSPSC 51433932: Efonidipine hydrochloride ethanolate

This classification denotes a calcium channel blocker with the molecular formula C34H38N3O7P.C2H6O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 84HJ0Q6TMN, chemically known as (+/-)-efonidipine hydrochloride ethanolate, but more generally known as efonidipine hydrochloride ethanolate, which bears US NIH Compound Identifier 163838. European Medicines Agency schedules efonidipine hydrochloride ethanolate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06471MIG.

Most nations, for tariff purposes, schedule efonidipine hydrochloride ethanolate under HS 29349990. SMILES: CCO.CC1=C(C(C(=C(N1)C)P2(=O)OCC(CO2)(C)C)C3CCCC(C3)[N+](=O)[O-])C(=O)OCCN(CC4CCCCC4)C5CCCCC5.CL.

UNSPSC 51433932 Efonidipine hydrochloride ethanolate is a Commodity code covering a specific pharmaceutical active ingredient used in emergency medicine and acute care settings. State and local governments procure this drug—and related advanced life support medications in the same family—primarily through municipal fire and rescue departments, public health agencies, and cooperative purchasing alliances serving multiple jurisdictions. The solicitations under this code reflect demand for formulary medications supplied in bulk quantities, with strict expiration, shelf-life, and delivery requirements tied to emergency response protocols.

The code sees activity across municipal and state purchasing bodies. The City of Tampa's Fire Rescue Department (Hillsborough County, Florida) issued an IFB in April 2026 for Advanced Life Support Medications including labetalol, epinephrine, adenosine, and diltiazem, with an estimated contract value of $40,000 and a one-year term plus renewal options. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products with pricing due March 26, 2026, serving participating state and local government facilities across multiple states including Oregon. A separate state-level market-research effort—the Texas Health and Human Services Commission's RFI for direct-to-manufacturer prescriptions (April 2026)—signals emerging interest in alternative supply models. Geographic activity appears concentrated in the South and Midwest, with Texas, Florida, and Minnesota showing recent procurement momentum. Vendors should note the emphasis on expiration-date warranties (nine months minimum from acceptance in Tampa), compliance with cGMP and DSCSA, and electronic data interchange capability in multistate cooperative vehicles.